Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Apartment Investment and Management Co (AIV) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance

Apartment Investment and Management CoTrade
Bio-Rad Laboratories, Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Apartment Investment and Management Co vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Apartment Investment and Management Co trades at $2.61 (market cap $376.16M), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 25.1× Apartment Investment and Management Co's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Apartment Investment and Management Co nearer its low. Which is the better fit depends on your goals.

AIVBIO
Market Cap
$376.16M$9.43B
Sector
Real EstateHealth
52-Week High
$7.93$356.25
52-Week Low
$2.59$241.71
Enterprise Value
$738.32M$9.18B

Returns comparison

Trailing returns across standard periods

About Apartment Investment and Management Co

Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment

Read more on AIV

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO